MaxCyte, Inc. CMO Appointment
25 4월 2018 - 3:01PM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
25 April 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte Appoints Dr Claudio Dansky Ullmann as Chief Medical
Officer
-- Dr Dansky Ullmann joins the Company as MaxCyte prepares for
clinical testing of its first cell therapy drug candidate
-- Brings more than 25 years of experience in clinical oncology and drug development
Gaithersburg, Maryland - 25 April 2018: MaxCyte (LSE: MXCT,
MXCR), the global cell-based medicines and life sciences company,
announced today that it has appointed Claudio Dansky Ullmann, MD, a
25+-year expert in clinical oncology and pharmaceutical research,
as its Chief Medical Officer (CMO). In his new role, Dr Dansky
Ullmann is responsible for overseeing clinical development of
MaxCyte's CARMA(TM) drug development program as the company's first
candidate, MCY-M11, is expected to enter the clinic this year.
Doug Doerfler, MaxCyte's CEO, said: "We are thrilled to welcome
Claudio to the MaxCyte team. His broad experience in cancer therapy
drug development will be invaluable at this stage in MaxCyte's
evolution from a cell engineering technology company to a drug
developer with a pipeline of CARMA drug candidate programs.
Furthermore, with his deep understanding of the development of
immuno-oncology therapies and other cancer treatments, Claudio will
help us to advance our Flow Electroporation(R) Technology to enable
our partners to make important medical breakthroughs."
Dr Dansky Ullmann was most recently the senior vice president
and head of clinical development at Infinity Pharmaceuticals,
where, as part of the executive leadership team, he oversaw all
clinical development and operations, shaped corporate strategy, and
was directly involved in business development activities as well as
investor and analyst interactions.
Previously, Dr Dansky Ullmann was a senior medical director and
global clinical lead for oncology clinical research in the Oncology
Therapy Area Unit at Takeda Pharmaceuticals.
Before joining Takeda, Dr Dansky Ullmann worked at the Cancer
Therapy Evaluation Program of the National Cancer Institute (NCI)
as a senior investigator participating in numerous early-phase and
late-phase clinical trials. During his career, Dr Dansky Ullmann
also held research roles at the National Institute of Health and
held postdoctoral fellowship positions in tumour immunotherapy and
drug resistance at the NCI. He also was involved in the development
of cell therapies and other immunotherapies at Biomira, Inc. Dr
Dansky Ullmann is a native of Argentina and earned his M.D. at the
School of Medicine, University of Buenos Aires. He completed his
medical oncology training at Guemes Private Hospital, Buenos
Aires.
"It's a very exciting time for me to join the team driving the
potential for MaxCyte's CARMA platform as we move towards clinical
testing of new therapeutics that will make a real difference in
treating patients with various cancers," said Dr Dansky Ullmann.
"In addition to being able to target solid tumours, we believe the
CARMA platform, and specifically its use of a non-viral approach,
has the potential to address some of the most significant issues
with current CAR-T therapies including challenging side effects as
well the complex, expensive and time-consuming manufacturing
processes found in traditional CAR therapies.
"I look forward to the start of our Phase I clinical trial for
our lead CARMA candidate, MCY-M11, which is expected to commence
dosing in patients with advanced peritoneal mesothelioma and
ovarian cancers in 2018," he added.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation Technology to enable
its partners across the biopharmaceutical industry to advance the
development of innovative medicines, particularly in cell therapy,
including gene editing and immuno-oncology. The Company has placed
its cutting-edge flow electroporation instruments worldwide,
including with nine of the top ten global biopharmaceutical
companies, and has more than 50 partnered programme licenses in
cell therapy including more than 20 licensed for clinical use. With
its robust delivery technology, MaxCyte helps its partners to
unlock the full potential of their products.
For more information, visit www.maxcyte.com
###
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley
Ryan McCarthy +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Suki Virji
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUWWCUPRGCC
(END) Dow Jones Newswires
April 25, 2018 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024